Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has achieved significant recognition in the field of vaccine research and development, particularly through its subsidiary Beijing Minhui Biological Technology Co., Ltd., which recently won the second prize of the Jiangsu Provincial Science and Technology Progress Award for its project on rapid confirmation and precise prevention of emerging viral infectious diseases [1][2]. Group 1: Project Recognition - The project "Key Technology Innovation and Application for Rapid Confirmation and Precise Prevention of Emerging Viral Infectious Diseases" addresses critical challenges in the prevention and control of new viral infectious diseases [1]. - The project was led by the Jiangsu Provincial Center for Disease Control and Prevention and nominated by the Provincial Health Commission, highlighting the importance of collaboration in public health initiatives [1]. Group 2: Vaccine Development - Minhui Biological's independently developed inactivated virus vaccine platform is a core component of the project, receiving high recognition for its innovation, practicality, and scientific value [2]. - The company has successfully obtained clinical trial approval from the National Medical Products Administration for its bivalent and quadrivalent inactivated enterovirus vaccines, with the quadrivalent vaccine currently in Phase I clinical trials [2]. - There are currently no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for the company [2]. Group 3: Strategic Implications - The recent award is seen as a validation of the company's commitment to independent innovation and its comprehensive strength in vaccine research and development, which is expected to enhance its core competitiveness and influence in the market [2]. - Successful development of these vaccines could further enrich the company's multi-valent vaccine portfolio, solidifying its market position and providing a strong foundation for sustainable growth [2].

格隆汇2月6日丨康泰生物(300601.SZ)公布，公司全资子公司北京民海生物科技有限公司（简称"民海生 物"）作为重要参与单位完成的"新发病毒性传染病快速确认与精准防控关键技术创新及应用"项目荣获 江苏省科学技术进步奖二等奖，系民海生物继荣获北京市科学技术进步奖二等奖、获批合成免疫学与疫 苗智造北京市重点实验室后，在科技创新领域取得的又一重要荣誉。该项目由江苏省疾病预防控制中心 牵头、省卫生健康委员会提名，民海生物凭借在肠道病毒灭活疫苗研发领域的核心技术创新与贡献，共 同荣获此项殊荣。 该项目直面新发病毒性传染病防控中"快速确认"与"精准防控"的关键难题，通过系列技术攻关，构建了 一套高效应对体系。其中，民海生物自主研发并提供关键技术支撑的肠道病毒灭活疫苗平台，是项目的 核心组成部分之一。该技术的创新性、实用性与科学价值，获得了评审专家的高度认可。公司基于该平 台研发的二价肠道病毒灭活疫苗（Vero细胞）及四价肠道病毒灭活疫苗（Vero细胞），已于2025年2月 分别成功获得国家药品监督管理局颁发的药物临床试验批准通知书，其中四价肠道病毒灭活疫苗（Vero 细胞）已处于Ⅰ期临床试验。目前全球尚无二价肠道病毒 ...

该项目直面新发病毒性传染病防控中"快速确认"与"精准防控"的关键难题，通过系列技术攻关，构建了 一套高效应对体系。其中，民海生物自主研发并提供关键技术支撑的肠道病毒灭活疫苗平台，是项目的 核心组成部分之一。该技术的创新性、实用性与科学价值，获得了评审专家的高度认可。公司基于该平 台研发的二价肠道病毒灭活疫苗（Vero细胞）及四价肠道病毒灭活疫苗（Vero细胞），已于2025年2月 分别成功获得国家药品监督管理局颁发的药物临床试验批准通知书，其中四价肠道病毒灭活疫苗（Vero 细胞）已处于Ⅰ期临床试验。目前全球尚无二价肠道病毒疫苗、四价肠道病毒疫苗获批上市。公司将积 极推动该等产品的临床研究，若该等疫苗研发成功，将有利于进一步丰富公司多联多价疫苗的布局，增 强公司的核心竞争力和市场地位，为公司持续稳健发展奠定坚实基础。 格隆汇2月6日丨康泰生物(300601.SZ)公布，公司全资子公司北京民海生物科技有限公司（简称"民海生 物"）作为重要参与单位完成的"新发病毒性传染病快速确认与精准防控关键技术创新及应用"项目荣获 江苏省科学技术进步奖二等奖，系民海生物继荣获北京市科学技术进步奖二等奖、获批合成免疫学与疫 苗智 ...